Monoclonal Antibodies & Immunotherapy to Treat Cancer: Current Knowledge, Emerging Targets and Future Perspectives
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2101
Special Issue Editors
Interests: monoclonal antibodies; cancer; antibodies; treatment; mAbs; immune checkpoint inhibitors; multispecific antibodies
Special Issues, Collections and Topics in MDPI journals
Interests: cancer research; medical oncology; non-small-cell lung cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Monoclonal antibodies (mAbs) are a unique type of targeted drugs which have transformed the therapeutics of cancer. During the last twenty-two years, from the approval of rituximab in 1997 until now, many engineered humanized or chimeric mAbs have been produced and validated in clinical trials, changing the way we understand and treat hematologic and solid malignancies.
The tremendous impact and success of mAbs in cancer management is based on their specificity and selectivity for specific antigens on target cells. MAbs mainly target and destroy cancer cells by interrupting specific oncogenic cell signaling, inducing apoptosis or carrying a conjugated drug, toxin or radioactive substance. One of the most successful applications of mAbs is to empower the immune system to eradicate cancer cells. With the advances in methodological and production techniques, significant improvements are expected in this class of medications, including, but not limiting to, bi-, tri- or multispecific mAbs, newer antibody–drug conjugates (ADCs), antibody-targeted nanoparticles and single-domain antibodies (sdAb).
This Special Issue will cover all aspects of monoclonal antibodies regarding their role in cancer treatment, recent advances in cancer immunotherapy using mAbs, as well as the upcoming antibody products which are investigated in cancer.
Dr. Foteinos-Ioannis Dimitrakopoulos
Prof. Dr. Haralabos Kalofonos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
